EXPLANATORY STATEMENT

*NATIONAL HEALTH ACT 1953*

*NATIONAL HEALTH (PRICE AND SPECIAL PATIENT CONTRIBUTION) AMENDMENT DETERMINATION 2024 (No. 10)*

*PB 131 of 2024*

**Authority**

This legislative instrument, made under section 85B of the *National Health Act 1953* (the Act), amends the *National Health (Price and Special Patient Contribution) Determination 2022* (PB 98 of 2022) (the Principal Determination).

Subsections 85B(2), (3) and (4) of the Act provide for the Minister to determine, respectively, determined prices, claimed prices and the circumstances in which the Commonwealth will pay a special patient contribution. The Principal Determination contains determinations of these matters.

**Variation and revocation**

Unless there is an express power to revoke or vary PB 98 of 2022 cited in this instrument and explanatory statement, subsection 33(3) of the *Acts Interpretation Act 1901* is relied upon to revoke or vary PB 98 of 2022.

**Purpose**

The Act provides for the Minister and the responsible persons to agree a price that is taken to be the appropriate maximum price of a brand of a pharmaceutical item for the purposes of Part VII of the Act (section 85AD). Section 85B of the Act applies if the Minister and the responsible person have been unable to reach an agreement on a price for the *pricing quantity*. Whether or not an agreement is made for the *pricing quantity*, section 85B also applies if the responsible person is dissatisfied with the *proportional ex-manufacturer prices* that will apply to other *pack quantities*.

Subsection 85B(2) provides that the Minister may determine, by reference to the *pricing quantity* of a brand of a pharmaceutical item, an amount that is taken to be the appropriate maximum price of the brand for the purposes of Part VII of the Act. This is termed the ‘Determined Price’ in the Determination.

Subsection 85B(3) provides that the Minister may determine, by reference to a *pack quantity* of a brand of the pharmaceutical item, an amount that is taken to be the price claimed by the responsible person for the *pack quantity* of the brand, for the purposes of Part VII of the Act. This is termed the ‘Claimed Price’ in the Determination.

The Determined Price is the *Approved Ex-Manufacturer Price (AEMP)* and is used as the basis for working out the Commonwealth price for the brand of the pharmaceutical item (section 98B of the Act); for *pack quantities* other than the *pricing quantity*, the *proportional ex-manufacturer price (PEMP)* is used as the basis. Approved pharmacists are entitled to receive a payment from the Commonwealth equal to the Commonwealth price less the applicable patient co-payment (section 99 of the Act).

The difference between the responsible person’s Commonwealth price for a *pack quantity* (i.e., the price that would be the Commonwealth price if the responsible person’s claimed price had become the *approved ex-manufacturer price* or the *proportional ex-manufacturer price* for that *pack quantity*) and the Commonwealth price for the *pack quantity* is defined in subsection 85B(5) of the Act as the *special patient contribution*. An approved pharmacist may charge a patient an amount equal to the special patient contribution, in addition to any other amount that may be charged (subsection 87(2A) of the Act).

Subsection 85B(4) of the Act provides that the Minister may determine the circumstances in which the Commonwealth is to pay the Special Patient Contribution for a brand. In such cases, the Commonwealth payment to the pharmacist is increased by the amount of the special patient contribution (subsection 99(2AA) of the Act) and the pharmacist may not charge the patient this amount (subsection 87(2A) of the Act).

The purpose of making subsection 85B(4) determinations is to enable patients for whom the base-priced brands (the ones without a special patient contribution) are not suitable, to obtain the higher priced brand (the one with the special patient contribution) without the need to pay the higher price. In such cases the Commonwealth pays the special patient contribution.

This instrument (the Determination) amends the Principal Determination by adding a brand premium for eight pharmaceutical items and increasing the brand premium for twenty-two pharmaceutical items on the PBS due to the requests by responsible persons and increasing the brand premium for two pharmaceutical items on the PBS due to an administrative error on the December schedule data. In addition, this instrument amends the Principal Determination by removing the brand premiums from two brands of one pharmaceutical item that is delisting from the PBS as requested by responsible persons. Moreover, this instrument amends the Principal Determination by removing the brand premiums from one brand of three pharmaceutical items due to supply issues with generic brands on the PBS and removing the brand premium for one brand of one pharmaceutical item due to the delist of the only premium-free brand for the item on the PBS. This is consistent with the Department’s policy that pharmaceutical companies are only able to charge brand premiums where there is at least one premium-free brand of the same medicine available on the PBS to allow for equitable access to medicines.

The amendments provided by this instrument take effect on 1 December 2024.

**Consultation**

This Determination affects certain responsible person with medicines listed on the PBS. Before a pharmaceutical benefit is listed on the PBS, and from time to time thereafter, price negotiations occur between the responsible person and the Minister for the purpose of reaching a price agreement for section 85AD of the Act. If the Minister and the responsible person do not agree on a price, further consultation occurs with the responsible person, and thereafter the Minister determines the price that will be the approved ex-manufacturer price for the brand. The Minister also determines the corresponding price claimed by the responsible persons which is used to calculate the special patient contribution that will apply to the brand.

The responsible persons affected by this Determination for imposing the brand premiums for dabigatran etexilate, minocycline, pramipexole, pregabalin, and terbinafine each made a submission about the claimed prices the Minister should determine in relation to their brands. For the following brands, the claimed price and brand premiums will be imposed for the listing of these brands consistent with the request made by the responsible person:

* Dabigatran etexilate
	+ capsule 110 mg (as mesilate), Pradaxa
	+ capsule 150 mg (as mesilate), Pradaxa
* Minocycline
	+ tablet 50 mg (as hydrochloride), Minomycin-50
* Pramipexole
	+ tablet containing pramipexole dihydrochloride monohydrate 125 micrograms, Sifrol
	+ tablet containing pramipexole dihydrochloride monohydrate 250 micrograms, Sifrol
* Pregabalin
	+ capsule 25 mg, Lyrica
	+ capsule 300 mg, Lyrica
* Terbinafine
	+ tablet 250 mg (as hydrochloride), Lamisil (Novartis Pharmaceuticals Australia Pty Ltd)

The responsible persons affected by this Determination for increases to existing brand premiums for amlodipine with valsartan, amlodipine with valsartan and hydrochlorothiazide, brinzolamide, carbamazepine, ciprofloxacin, diclofenac, letrozole, telmisartan, and telmisartan with hydrochlorothiazide, each made a submission about the claimed price the Minister should determine in relation to their brand. For the following brands, the claimed price will be increased and to give effect to increased brand premiums for the listing of these brands consistent with the request made by the responsible person:

* Amlodipine with valsartan
	+ tablet 5 mg (as besilate)-80 mg, Exforge 5/80
	+ tablet 5 mg (as besilate)-160 mg, Exforge 5/160
	+ tablet 5 mg (as besilate)-320 mg, Exforge 5/320
	+ tablet 10 mg (as besilate)-160 mg, Exforge 10/160
	+ tablet 10 mg (as besilate)-320 mg, Exforge 10/320
* Amlodipine with valsartan and hydrochlorothiazide
	+ tablet 5 mg (as besilate)-160 mg-12.5 mg, Exforge HCT 5/160/12.5
	+ tablet 5 mg (as besilate)-160 mg-25 mg, Exforge HCT 5/160/25
	+ tablet 10 mg (as besilate)-160 mg-12.5 mg, Exforge HCT 10/160/12.5
	+ tablet 10 mg (as besilate)-160 mg-25 mg, Exforge HCT 10/160/25
	+ tablet 10 mg (as besilate)-320 mg-25 mg, Exforge HCT 10/320/25
* Brinzolamide
	+ eye drops 10 mg per mL, 5 mL, Azopt
* Carbamazepine
	+ tablet 100 mg, Tegetrol 100
	+ tablet 200 mg, Tegetrol 200
* Ciprofloxacin
	+ eye drops 3 mg (as hydrochloride) per mL, 5 mL, Ciloxan
* Diclofenac
	+ tablet (enteric coated) containing diclofenac sodium 25 mg, Voltaren 25
	+ tablet (enteric coated) containing diclofenac sodium 50 mg, Voltaren 50
* Letrozole
	+ tablet 2.5 mg, Femara 2.5 mg
* Telmisartan
	+ tablet 40 mg, Micardis
	+ tablet 80 mg, Micardis
* Telmisartan with hydrochlorothiazide
	+ tablet 40 mg-12.5 mg, Micardis Plus 40/12.5 mg
	+ tablet 80 mg-12.5 mg, Micardis Plus 80/12.5 mg
	+ tablet 80 mg-25 mg, Micardis Plus 80/25 mg

The pharmaceutical items affected by this Determination for increases to the existing brand premiums for valproic acid. The responsible person has requested an increase to the brand premiums. For the following brands, the claimed prices will be increased to give effect to the increased brand premiums:

* Valproic acid
	+ tablet (enteric coated) containing sodium valproate 200 mg, Epilim EC
	+ tablet (enteric coated) containing sodium valproate 500 mg, Epilim EC

For the brand Depo-Provera, the claimed price and brand premium will be removed from the brand consistent with the request made by the responsible person to delist the brand from the PBS. The delist request was considered by the PBAC as not resulting in an unmet clinical need.

For the brand Atozet®, the claimed price and brand premium will be removed due to the supply issues with the premium-free brands of three strengths (10 mg-10 mg, 10 mg-40 mg, and 10 mg-80 mg) of ezetimibe with atorvastatin listed on the PBS. The responsible person of this brand agreed to the removal of the brand premiums. No additional consultation with experts was undertaken regarding this Determination because consultation with the affected responsible person, which informed the making of this Determination, drew on the knowledge of persons with relevant expertise.

For the brand Orudis SR 200, the claimed price and brand premium will be removed due to the delisting of the only alternative, premium-free brand of ketoprofen capsules on the PBS. The responsible person of this brand agreed to the removal of the brand premium. No additional consultation with experts was undertaken regarding this Determination because consultation with the affected responsible person, which informed the making of this Determination, drew on the knowledge of persons with relevant expertise.

A provision by provision description of the Determination is contained in the Attachment.

This Determination commences on 1 December 2024.

This Determination is a legislative instrument for the purposes of the *Legislation Act 2003*.

ATTACHMENT

**PROVISION BY PROVISION DESCRIPTION OF THE *NATIONAL HEALTH (PRICE AND SPECIAL PATIENT CONTRIBUTION) AMENDMENT DETERMINATION 2024 (No .10)***

***(PB 131 of 2024)***

**Section 1 Name of Determination**

This section provides that the Determination is the *National Health (Price and Special Patient Contribution) Amendment Determination 2024 (No. 10)* and may also be cited as PB 131 of 2024.

**Section 2 Commencement**

This section provides that the Determination commences on 1 December 2024.

**Section 3 Amendment of the *National Health (Price and Special Patient Contribution) Determination 2022* (PB 98 of 2022).**

This section provides that Schedule 1 amends the *National Health (Price and Special Patient Contribution) Determination 2022* (PB 98 of 2022).

**Schedule 1 Amendments commencing 1 December 2024**

Schedule 1 sets out the amendments to the Principal Determination which commence on 1 December 2024.

**SUMMARY OF CHANGES**

***SCHEDULE 1***

**Brands with new brand price premiums**

* Dabigatran etexilate
	+ capsule 110 mg (as mesilate), Pradaxa
	+ capsule 150 mg (as mesilate), Pradaxa
* Minocycline
	+ tablet 50 mg (as hydrochloride), Minomycin-50
* Pramipexole
	+ tablet containing pramipexole dihydrochloride monohydrate 125 micrograms, Sifrol
	+ tablet containing pramipexole dihydrochloride monohydrate 250 micrograms, Sifrol
* Pregabalin
	+ capsule 25 mg, Lyrica
	+ capsule 300 mg, Lyrica
* Terbinafine
	+ tablet 250 mg (as hydrochloride), Lamisil (Novartis Pharmaceuticals Australia Pty Ltd)

**Brands with increase brand premiums**

* Amlodipine with valsartan
	+ tablet 5 mg (as besilate)-80 mg, Exforge 5/80
	+ tablet 5 mg (as besilate)-160 mg, Exforge 5/160
	+ tablet 5 mg (as besilate)-320 mg, Exforge 5/320
	+ tablet 10 mg (as besilate)-160 mg, Exforge 10/160
	+ tablet 10 mg (as besilate)-320 mg, Exforge 10/320
* Amlodipine with valsartan and hydrochlorothiazide
	+ tablet 5 mg (as besilate)-160 mg-12.5 mg, Exforge HCT 5/160/12.5
	+ tablet 5 mg (as besilate)-160 mg-25 mg, Exforge HCT 5/160/25
	+ tablet 10 mg (as besilate)-160 mg-12.5 mg, Exforge HCT 10/160/12.5
	+ tablet 10 mg (as besilate)-160 mg-25 mg, Exforge HCT 10/160/25
	+ tablet 10 mg (as besilate)-320 mg-25 mg, Exforge HCT 10/320/25
* Brinzolamide
	+ eye drops 10 mg per mL, 5 mL, Azopt
* Carbamazepine
	+ tablet 100 mg, Tegetrol 100
	+ tablet 200 mg, Tegetrol 200
* Ciprofloxacin
	+ eye drops 3 mg (as hydrochloride) per mL, 5 mL, Ciloxan
* Diclofenac
	+ tablet (enteric coated) containing diclofenac sodium 25 mg, Voltaren 25
	+ tablet (enteric coated) containing diclofenac sodium 50 mg, Voltaren 50
* Letrozole
	+ tablet 2.5 mg, Femara 2.5 mg
* Telmisartan
	+ tablet 40 mg, Micardis
	+ tablet 80 mg, Micardis
* Telmisartan with hydrochlorothiazide
	+ tablet 40 mg-12.5 mg, Micardis Plus 40/12.5 mg
	+ tablet 80 mg-12.5 mg, Micardis Plus 80/12.5 mg
	+ tablet 80 mg-25 mg, Micardis Plus 80/25 mg
* Valproic acid
	+ tablet (enteric coated) containing sodium valproate 200 mg, Epilim EC
	+ tablet (enteric coated) containing sodium valproate 500 mg, Epilim EC

**Deletion of brands**

* Medroxyprogesterone
	+ injection containing medroxyprogesterone acetate 150 mg in 1 mL vial, Depo-Provera

**Brands that no longer have a brand premium**

* Ezetimibe with atorvastatin
	+ tablet 10 mg-10 mg, Atozet
	+ tablet 10 mg-40 mg, Atozet
	+ tablet 10 mg-80 mg, Atozet
* Ketoprofen
	+ capsule 200 mg (sustained release), Orudis SR 200

**Statement of Compatibility with Human Rights**

*Prepared in accordance with Part 3 of the Human Rights (Parliamentary Scrutiny) Act 2011*

**National Health (Price and Special Patient Contribution) Amendment Determination 2024 (No. 10) (PB 131 of 2024)**

This legislative instrument is compatible with the human rights and freedoms recognised or declared in the international instruments listed in section 3 of the *Human Rights (Parliamentary Scrutiny) Act 2011*.

**Overview of the Legislative Instrument**

This legislative instrument, made under section 85B of the *National Health Act 1953* (the Act), amends the *National Health (Price and Special Patient Contribution) Determination 2022* (the Principal Determination), which provides for price determinations in relation to brands of pharmaceutical items listed on the Pharmaceutical Benefits Scheme (PBS) for which the Minister and the Responsible Persons have not been able to make a price agreement. It also provides for the circumstances in which the Commonwealth will pay the special patient contribution resulting from these price determinations. This instrument (the Amendment Determination) amends the Principal Determination by inserting claimed prices to provide new brand premiums for eight pharmaceutical items and varying claimed prices to increase the brand premium for twenty-two pharmaceutical items on the PBS due to requests by responsible persons. In addition, this instrument amends the Principal Determination by removing the brand premium for two pharmaceutical items that are delisting from the PBS as requested by the responsible persons and three pharmaceutical items due to supply issues with generic brands for these items on the PBS. These changes take effect on 1 December 2024.

**Human rights implications**

This legislative instrument engages Articles 2 and 12 of the International Covenant on Economic, Social and Cultural Rights by assisting with the progressive realisation by all appropriate means of the right of everyone to the enjoyment of the highest attainable standard of physical and mental health.

The PBS is a benefit scheme which assists with advancement of this human right by providing for subsidised access by patients to medicines.

The removal of the brand premium and claimed price from the brand Atozet and Orudis SR 200 were requested consistent with the longstanding Government policy that pharmaceutical companies are only able to charge brand price premiums where there is at least one premium free brand of that medicine available through the PBS. This allows for continued access for eligible Australians to these remaining PBS listed brands of this medicine at subsidised prices, without the need to pay a premium.

The Depo-Provera syringe form of medroxyprogesterone is premium-free and remains on the PBS for following the deletion of Depo-Provera vial. Both forms are deemed substitutable under the PBS listing.

Eligible Australians may continue to access any one of the remaining brands for these pharmaceutical items at subsidised prices as they are flagged for substitution by pharmacists against brands with a brand premium.

All brands subsidised by the PBS are evaluated by the Therapeutic Goods Administration for quality and safety and determined to be bioequivalent, which means they are clinically equivalent and work in the same way. Removing items with brand price premiums will not result in negative financial impact for patients, therefore ensuring their rights to social security are maintained. The recommendatory role of the Pharmaceutical Benefits Advisory Committee ensures that decisions about subsidised access to medicines on the PBS are evidence-based.

The recommendatory role of the Pharmaceutical Benefits Advisory Committee ensures that decisions about subsidised access to medicines on the PBS are evidence-based.

**Conclusion**

This legislative instrument is compatible with human rights because it advances the protection of human rights.

**Eden Simon**

 **Acting Assistant Secretary**

**Pricing and PBS Policy Branch**

**Technology Assessment and Access Division**

**Department of Health and Aged Care**